cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21 mars 2024 16h05 HE | Cargo Therapeutics, Inc.
CARGO Therapeutics today provided a business update and reported financial results for the quarter and year ending December 31, 2023.
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h05 HE | Cargo Therapeutics, Inc.
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
13 déc. 2023 16h05 HE | Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Announces Scientific Advisory Board
06 déc. 2023 08h05 HE | Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
23 nov. 2020 08h00 HE | TeneoBio, Inc
NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
21 oct. 2020 08h00 HE | TeneoBio, Inc
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
08 juin 2020 08h00 HE | TeneoBio, Inc
NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...